Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure

[1]  A. Mallet,et al.  Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial , 2001, Circulation.

[2]  J. Cleland,et al.  Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS‐II, BEST, AMIOVIRT, V‐MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure , 2001, European journal of heart failure.

[3]  A. Charlesworth,et al.  Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.

[4]  M. Metra,et al.  A rationale for the use of β-blockers as standard treatment for heart failure , 2000 .

[5]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[6]  J. Cleland,et al.  Is the prognosis of heart failure improving? , 1999, Journal of the American College of Cardiology.

[7]  F. McAlister,et al.  β-Blockers For Congestive Heart Failure , 2000 .

[8]  F. McAlister,et al.  Beta-blockers for congestive heart failure: what is the current consensus? , 2000, Drugs & aging.

[9]  J. Cleland,et al.  Is the prognosis of heart failure improving? , 2000, European journal of heart failure.

[10]  S. Yusuf,et al.  Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. , 1999, Circulation.

[11]  F. McAlister,et al.  The Treatment and Prevention of Coronary Heart Disease in Canada: Do Older Patients Receive Efficacious Therapies? , 1999 .

[12]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[13]  A. Camm,et al.  Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. , 1999, Circulation.

[14]  J. Cleland,et al.  Has the survival of the heart failure population changed? Lessons from trials. , 1999, The American journal of cardiology.

[15]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[16]  U. Laufs,et al.  THERAPIE DER HERZINSUFFIZIENZ MIT BETA-REZEPTORENBLOCKERN , 1999 .

[17]  M. Gheorghiade,et al.  Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. , 1998, Journal of the American College of Cardiology.

[18]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[19]  M. Bristow,et al.  Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. , 1997, The American journal of cardiology.

[20]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[21]  R. Dietz,et al.  [Therapy of heart failure with beta-blockers?]. , 1997, Zeitschrift fur Kardiologie.

[22]  R. Dietz,et al.  Therapie der Herzinsuffizienz mit β-Blockern? , 1997, Zeitschrift für Kardiologie.

[23]  M. Bristow,et al.  Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. , 1996, Circulation.

[24]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[25]  B. Pitt.  Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). , 1996, The American journal of cardiology.

[26]  D. Mancini,et al.  Rationale for treatment of patients with chronic heart failure with adrenergic blockade. , 1996, JAMA.

[27]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[28]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[29]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[30]  A. Merrill,et al.  EDEMA AND DECREASED RENAL BLOOD FLOW IN PATIENTS WITH CHRONIC CONGESTIVE HEART FAILURE: EVIDENCE OF "FORWARD FAILURE" AS THE PRIMARY CAUSE OF EDEMA. , 1946, The Journal of clinical investigation.